Concurrent Genetic Alterations and Other Biomarkers Predict Treatment Efficacy of EGFR-TKIs in EGFR-Mutant Non-Small Cell Lung Cancer: A Review

Concurrent Genetic Alterations and Other Biomarkers Predict Treatment Efficacy of EGFR-TKIs in EGFR-Mutant Non-Small Cell Lung Cancer: A Review

Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) greatly improve the survival and quality of life of non-small cell lung cancer (NSCLC) patients with EGFR mutations. However, many patients exhibit de novo or primary/early resistance. In addition, patients who initially respond...

Full description

Bibliographic Details
Main Authors: Yijia Guo, Jun Song, Yanru Wang, Letian Huang, Li Sun, Jianzhu Zhao, Shuling Zhang, Wei Jing, Jietao Ma, Chengbo Han
Format: Article
Language:English
Published: Frontiers Media S.A. 2020-12-01
Series:Frontiers in Oncology
Subjects:
non-small cell lung cancer
concurrent genetic alteration
epidermal growth factor receptor tyrosine kinase inhibitors
PD-L1 expression
BIM polymorphism
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2020.610923/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2020.610923/full

Similar Items